Company intelligence / Profile preview
Neuropore Therapies, Inc.
San Diego, California, United Statesneuropore.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Phase 2
01
Overview
Neuropore Therapies has completed a Phase 1 clinical trial for NPT520‑34 in healthy volunteers and is advancing this candidate for Parkinson’s disease and ALS. Its TLR2/TLR9 antagonist program is supported by grants from The Michael J. Fox Foundation and the ALS Association, with preclinical data showing reduction of neuroinflammation and protein pathology. The company previously outlicensed its first clinical candidate UCB0599 to UCB Pharma after successful early-stage trials.[4][5]
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecules[2][4][6]
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
UCB Pharma (collaboration on UCB0599/NPT200‑11)[8]Global Cancer Technology (licensee for autophagy modulators)[5]The Michael J. Fox Foundation for Parkinson's Research [4]The ALS Association [5]
Beyond the preview
Go deeper on Neuropore Therapies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuropore Therapies, Inc..